Daily Cosmetic Research Analysis

OBJECTIVES: To investigate whether a TiF METHODS: Fifty-one patients/241 teeth were randomized into four groups. DH was measured using a 10-point visual analog scale after evaporative and tactile stimuli at baseline, immediately after application, and after 1, 3, and 6 months. OHRQoL was evaluated using the OHIP-14 questionnaire at baseline and after 1, 3, and 6 months. Statistical analyses included one-way ANOVA, Fisher's exact test, Kruskal-Wallis and DSCF post-hoc, Friedman's test and Durbin-Conover post-hoc, and mixed factorial ANOVA with Tukey post-hoc (α=0.05). RESULTS: All products reduced DH pain over time (p < 0.001). For evaporative stimulus, NaF varnish was outperformed by both toothpastes at 3 months, and by Elmex Opti-namel at 6 months (p = 0.048). For tactile stimulus, Biomin F was less effective than NaF varnish immediately after application (p = 0.028), but no other inter-group differences were observed. All products equally improved OHRQoL (p < 0.001), but the improvement was classified as low. CONCLUSION: All products improved OHRQoL, but Elmex Opti-namel provided the most effective pain relief after 6 months. CLINICAL SIGNIFICANCE: All products relieved pain and improved OHRQoL. However, both toothpastes presented higher DH pain relief than the NaF varnish after 3 months, and Elmex Opti-namel outperformed the NaF varnish after 6 months. Therefore, bioactive glass- and polyvalent metal-containing toothpastes are effective, noninvasive options for managing DH and enhancing patient comfort.

INTRODUCTION: Patients with early breast cancer (EBC) can be treated with accelerated partial breast irradiation (APBI). The objective of this study was to determine if a three-fraction APBI schedule is feasible for these patients. METHODS: This single-institutional, phase 2 study included patients with age ≥45 years, tumor size <3.5 cm, negative nodes, negative surgical margins, and unicentric tumors. Patients were treated with 3D-CRT technique with a dose of 22.5 Gy in 3 fractions on 3 consecutive days. The primary end point of the study was cosmesis as assessed by physicians at 3 years. Secondary end points were cosmesis as assessed by patients, dosimetry, acute and late toxicities, disease-free and overall survival. RESULTS: From October 2019 to October 2022, 49 patients were treated. Mean age of the patients was 55 years (range 40-75). At 3 years, physician- and patient-reported cosmetic results were excellent/good/fair in 33 (67%)/14 (29%)/2 (4%) of patients and in 29 (59%)/16 (33%)/4 (8%) of patients, respectively. Acute dermatitis grades 1 and 2 were observed in 14 (29%) and 3 (6%) of patients, respectively. At 6 months, breast edema, skin induration, subcutaneous fibrosis, pain, and pigmentation were observed in 3 (6%), 6 (12%), 3 (6%), 2 (4%), and 8 (16%) of patients, respectively. At 3 years, 1 (2%) patient had mild pain; no breast edema, skin induration, subcutaneous fibrosis, or pigmentation was observed. At a median follow-up of 39 months (range 24-60), there were no local/regional recurrences. One patient developed distant metastases in the bones, liver, and lungs at 46 months. All patients were alive at last follow-up. CONCLUSION: In patients with EBC, three-fraction APBI is feasible. Physician- and patient-reported cosmesis was excellent/good in 96% and 92% of patients, respectively. Late effects were only grade 1.

BACKGROUND: Cosmetic stature lengthening (CSL) is an elective orthopedic procedure performed to increase height. While clinical outcomes often define technical success, the broader effects on patients’ quality of life, functional recovery, and psychosocial well-being may be inadequately assessed. This review evaluates current outcome measures used in CSL studies in order to identify gaps in capturing patient-centered experiences and life impact outcomes. METHODS: Following the JBI methodology and PRISMA-ScR guidelines, a comprehensive literature search covering publications up to May 12, 2025, was conducted across MEDLINE, Embase, Cochrane Library, Web of Science, and Scopus. Studies focused on CSL with extractable outcome data were included. Outcomes were categorized using the Core Outcome Measures in Effectiveness Trials (COMET) taxonomy. RESULTS: Twenty studies met the inclusion criteria, reporting 410 outcomes grouped into 51 categories and 15 domains across four core areas: adverse events (3%), life impact (21%), physiological/clinical (75%), and resource use (1%). Only 25% of studies assessed quality of life, and while 55% measured patient satisfaction, most of these relied on unvalidated tools. Social functioning, an essential aspect of post-treatment well-being, was the least reported domain (15%). CONCLUSION: Outcome reporting in CSL is heavily skewed toward clinical metrics, with insufficient attention given to patient-centered measures such as quality of life, psychosocial well-being, and functional recovery. The lack of validated outcome measurement instruments impedes comparability across studies and limits evidence-based decision-making. Future research should prioritize standardized, validated patient-reported outcome measures to bridge the gap between technical success and meaningful patient experiences. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13018-025-06041-2.